Z94.0 Insurance Policy Changes

ICD-10 Z94.0 is officially defined as "Kidney transplant status." code Z94.0 is referenced in 18 tracked payer policy changes from Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z94.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Jul 16, 2026Medium impact
Laboratory Testing for Transplantation Rejection 2.02.55
Gene expression profiling (AlloMap) is considered medically appropriate for the management of individuals after heart transplantation when the individual is age 15 years or older, is 55 days to five years post-transplant, and has stable heart allograft function, including no signs or symptoms of congestive heart failure, a current echocardiogram with left ventricular ejection fraction of at least 45%, no severe cardiac allograft vasculopathy, no more than one episode of moderate or severe cellular rejection within the past year, and no history or evidence of antibody mediated rejection with associated hemodynamic compromise. Measurement of donor-derived cell-free DNA (e.g., AlloSure, myTAIHEART, Prospera, Viracor TRAC, Clarava, Tuteva) and of donor and third party-induced CD154+ T-cytotoxic memory cells (e.g., Pleximark) are considered investigational for the management of individuals after organ transplantation, including detection of acute transplant rejection or transplant graft dysfunction. The Heart Molecular Microscope Diagnostic System (MMDx-Heart) and the Kidney Molecular Microscope Diagnostic System (MMDx-Kidney) are also considered investigational for the same purposes.
Blue Cross & Blue Shield of Mississippi · Effective Jun 15, 2026Medium impact
Immunoglobulin Therapy
BCBSMS's Immunoglobulin Therapy policy states that prior authorization is required, and the 06/15/2026 update added Yimmugo to the products not covered on any BCBSMS Formulary. The same effective-dated update revised the medically necessary criteria for formulary intravenous and subcutaneous immunoglobulin therapy and changed the investigational list to specify sepsis in adults. Alyglo, Asceniv, Bivigam, Cuvitru, Flebogamma DIF, Gammagard S/D, Gammaplex, GamaSTAN, Hyqvia, Panzyga and Yimmugo are listed as not covered.
Aetna · Identified Oct 1, 2026Medium impact
Donor Lymphocyte Infusion (CPB 0638, reviewed 2026-09-29)
Aetna considers donor lymphocyte infusion medically necessary for persons who have had a prior medically necessary allogeneic bone marrow or peripheral stem cell transplantation. Several uses are considered experimental, investigational, or unproven, including GCSF-stimulated donor lymphocyte infusions for relapsed disease, intrathecal donor lymphocyte infusion, modified donor lymphocytes, reduced-dose infusion for Epstein-Barr virus-related post-transplant lymphoproliferative disease, pre-transplant infusion of extracorporeal photochemotherapy-treated donor lymphocytes for solid organ transplant, and donor lymphocyte-derived natural killer cells for melanoma. The policy does not apply to FDA-approved chimeric antigen receptor therapy, which is addressed in CPB 0920 and CPB 0924.
Aetna · Identified Sep 29, 2026Medium impact
Adoptive Immunotherapy and Cellular Therapy (CPB 0641, reviewed 2026-09-25)
Aetna considers adoptive immunotherapy using tumor-infiltrating lymphocytes (TILs) or interleukin-2 activated lymphokine-activated killer (LAK) cells experimental, investigational or unproven for a long list of indications, including Alzheimer disease, esophageal, gynecologic, head and neck, hepatocellular, lung, glioblastoma, renal cell, pancreatic and other malignancies, because there is not adequate evidence that it is more beneficial than IL-2 alone. Melanoma is excluded from that list for lifileucel (Amtagvi), an FDA-approved TIL therapy. Cellular therapy (including embryonic cell, fresh cell, glandular, live cell, MAGE-A4 cell, organotherapy and xenotransplant therapy) is considered experimental, investigational or unproven for a long list of indications due to lack of adequate evidence, including angina, arthritis, diabetes, heart failure, hypertension, ischemic heart disease, ischemic stroke, motor neuron diseases, osteoarthritis and focal cartilage defects of the knee, peripheral arterial disease, and traumatic brain injury. Cancer is excluded from that list for afamitresgene autoleucel (Tecelra), an FDA-approved MAGE-A4-directed TCR T-cell therapy for synovial sarcoma. The policy also lists CAR T-cell therapy for solid tumors and virus-specific T-cell lymphocyte therapy for viral infections as experimental, investigational or unproven. HCPCS code S2107 (adoptive immunotherapy per course of treatment) and M0075 (cellular therapy) are listed as not covered for the indications in the policy.
Aetna · Identified Aug 19, 2026Medium impact
Kidney Transplantation (CPB 0493, reviewed 2026-07-30)
Aetna considers kidney transplantation medically necessary for members who meet the transplanting institution's selection criteria. Where no institution criteria apply, the member must complete an evaluation and be accepted by the kidney transplant committee, meet the transplanting institution's protocol age criteria, have no malignancy except the listed exceptions, and meet the policy's infection, cardiovascular, pulmonary, hepatic and severity-of-disease criteria. Aetna considers belatacept (Nulojix) medically necessary for preventing acute rejection in kidney transplant recipients who are sero-positive for Epstein-Barr virus, and equine anti-thymocyte globulin (Atgam) medically necessary for prophylaxis or treatment of allograft rejection in renal transplantation in combination with conventional therapy, and for moderate to severe aplastic anemia in persons who are not suitable candidates for bone marrow transplantation, while gene microarray, donor-derived cell-free DNA, urinary biomarker, TruGraf and AI/ML graft survival tests are experimental, investigational, or unproven for the indications listed.
Aetna · Identified Aug 17, 2026Medium impact
Hepatitis Screening (CPB 0835, reviewed 2025-12-09)
Aetna considers hepatitis B screening medically necessary for listed groups, including people on hemodialysis, blood or organ donors, pregnant women, people with HIV, injection drug users, men who have sex with men, and people born in regions with a 2% or higher HBV prevalence. Hepatitis C screening is medically necessary for listed groups, and one-time HCV testing without prior risk assessment is medically necessary for adults aged 18 years and older. Hepatitis D screening is medically necessary for people with HBsAg-positive hepatitis B infection and significant risk factors, while hepatitis E screening in the peri-transplant period is experimental, investigational, or unproven.
Aetna · Identified Aug 17, 2026Medium impact
ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) (CPB 0780, reviewed 2026-04-27)
Aetna considers the ADAMTS13 assay medically necessary for assessing prognosis in persons with thrombotic thrombocytopenic purpura (TTP), and for distinguishing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA, also called transplant-associated TMA) from TTP in persons with overlapping features when the test will be used to inform treatment. Aetna considers the assay experimental, investigational, or unproven for the uses it lists because of insufficient evidence, including sepsis-associated thrombotic microangiopathy, hemolytic uremic syndrome, acute myelogenous leukemia, colorectal cancer survival, COVID-19, cerebral infarction, and ADAMTS13 mutation testing for non-cirrhotic portal hypertension.
Aetna · Identified Aug 17, 2026Medium impact
Flow Cytometry, Ektacytometry, DNA Ploidy, and S-phase Fraction (CPB 0351, reviewed 2026-05-21)
Aetna considers flow cytometry for cell surface markers medically necessary for listed conditions, including abnormal tissue, bone marrow or blood histology suspicious for lymphoma, leukemia or myelodysplastic syndrome, multiple myeloma, paroxysmal nocturnal hemoglobinuria, primary immunodeficiencies, Sezary syndrome diagnosis, and T-cell monitoring for HIV infection and AIDS. Flow-cytometry-derived DNA ploidy or S-phase fraction is medically necessary only in localized cancers without metastatic disease, namely endometrial adenocarcinoma, gastric cancer, mediastinal neuroblastoma, medulloblastoma, ovarian carcinoma, partial hydatidiform mole, prostatic adenocarcinoma, renal cell adenocarcinoma and urinary bladder carcinoma, and only when the prognostic information will affect treatment decisions. Ektacytometry is medically necessary for red blood cell cytoskeleton and hydration disorders when red blood cell morphology does not provide a clear diagnosis. The red blood cell adhesion index for all indications, DNA ploidy or S-phase testing in breast, cervical, colorectal, non-small cell lung, small cell lung and pediatric intracranial tumors, and microfluidic flow adhesion assays for sickle cell disease are experimental, investigational or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Talimogene Laherparepvec (Imlygic) (CPB 0900, reviewed 2026-04-14)
Aetna considers talimogene laherparepvec (Imlygic) medically necessary for metastatic, unresectable, limited resectable, or borderline resectable cutaneous, subcutaneous, and nodal melanoma lesions when used as a single agent, and for palliative treatment of nodal Merkel cell carcinoma as a single agent when the member has a contraindication to or progression on anti-PD-L1 or anti-PD-1 therapy and curative surgery or radiation therapy is not feasible. Aetna considers Imlygic in combination with other immune therapies, such as ipilimumab and pembrolizumab, experimental, investigational, or unproven. Continuation of therapy is considered medically necessary when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Aetna · Identified Aug 15, 2026Medium impact
Remote Ischemic Conditioning (CPB 0814, reviewed 2025-11-20)
Aetna's Clinical Policy Bulletin 0814 considers remote ischemic conditioning experimental, investigational, or unproven for many indications because its effectiveness has not been established. The listed indications include acute coronary syndromes in individuals undergoing percutaneous coronary intervention, prevention of contrast-induced acute kidney injury, improvement of outcomes in individuals with acute ischemic stroke undergoing intravenous thrombolysis, improvement of outcomes following orthopedic surgery, sepsis management, and treatment of ulcerative colitis. The bulletin states that there are no specific codes for remote ischemic conditioning.
Aetna · Identified Aug 14, 2026Medium impact
Near-Infrared Vascular Imaging and Near-Infrared Fluorescence Imaging (CPB 0846, reviewed 2025-12-04)
Aetna considers near-infrared vascular imaging and near-infrared fluorescence imaging experimental, investigational, or unproven for the indications listed in the policy. These include intra-operative fluorescence imaging of extra-hepatic bile ducts with indocyanine green for assessment of liver function, intra-parenchymal near-infrared spectroscopy for detection of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage, sentinel lymph node detection with indocyanine green in cutaneous melanoma and oral squamous cell carcinoma, and Cision InVision short-wave infrared imaging for pathological imaging. Other listed indications include diagnosis of peripheral artery disease, diagnosis of rheumatoid arthritis, sentinel lymph node mapping in endometrial cancer, transcutaneous NIR spectroscopy for monitoring kidney and liver allograft perfusion, and near-infrared vascular imaging systems for assessment of cutaneous wound and guiding vascular access.
Aetna · Identified Aug 14, 2026Medium impact
Donor Lymphocyte Infusion (CPB 0638, reviewed 2025-11-12)
Aetna considers donor lymphocyte infusion (DLI) medically necessary for persons who have had a prior, medically necessary allogeneic bone marrow or peripheral stem cell transplantation. Aetna considers these uses experimental, investigational, or unproven: GCSF-stimulated DLI for relapsed disease after allogeneic hematopoietic cell transplantation, intrathecal DLI, modified donor lymphocytes (such as depleted, expanded, T-cell depleted, CAR-modified or genetically modified cells), pre-transplant infusion of extracorporeal photochemotherapy-treated donor lymphocytes to prevent graft rejection after solid organ transplantation, reduced-dose DLI for Epstein-Barr virus-related post-transplant lymphoproliferative disease, and donor lymphocyte-derived natural killer cells for melanoma. The policy does not apply to FDA-approved CAR T therapy, which involves modification of autologous lymphocytes.
Aetna · Identified Aug 12, 2026Medium impact
Belimumab (Benlysta) (CPB 0818, reviewed 2026-06-10)
For commercial plans, Aetna considers belimumab (Benlysta) medically necessary for members 5 years of age or older with active systemic lupus erythematosus (SLE) or active lupus nephritis when the listed criteria are met. For SLE, the member must be positive for SLE-relevant autoantibodies before starting therapy and must be receiving a standard SLE treatment such as glucocorticoids, antimalarials, or immunosuppressants. Aetna considers all other indications experimental, investigational, or unproven, and lists severe active central nervous system lupus and use of belimumab in combination with other biologics as exclusions.
Aetna · Identified Aug 12, 2026Medium impact
Adoptive Immunotherapy and Cellular Therapy (CPB 0641, reviewed 2025-10-01)
Aetna's Clinical Policy Bulletin 0641 considers adoptive immunotherapy using tumor-infiltrating lymphocytes or IL-2-activated LAK cells, and a broad list of cellular therapies, experimental, investigational or unproven for the indications it names. Those indications include most cancers, Alzheimer disease, COVID-19, heart failure, ischemic heart disease, orthopedic and musculoskeletal disorders, and minimization of general immunosuppression in kidney transplant recipients. The policy names exceptions for lifileucel (Amtagvi) in melanoma and afamitresgene autoleucel (Tecelra) in synovial sarcoma, and it lists CAR T-cell therapy for solid tumors and virus-specific T-cell lymphocyte therapy for viral infections among the unproven uses.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Plasma Exchange
Plasma exchange is covered as medically necessary for listed conditions, including severe mixed cryoglobulinemia with multiple manifestations, catastrophic antiphospholipid syndrome, thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, HELLP syndrome of pregnancy, chronic inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis in crisis, and ABO-incompatible kidney transplantation. Listed investigational applications include rheumatoid arthritis, systemic lupus erythematosus, sepsis, asthma, neuromyelitis optica, and multiple sclerosis with a chronic progressive or relapsing remitting course. BCBSMS makes no payment for services that are not documented to be medically necessary.
Florida Blue · Identified Jun 16, 2026Medium impact
Coding Newsletter - Chronic Kidney Disease
Florida Blue has updated coding guidelines for Chronic Kidney Disease (CKD), emphasizing the requirement for providers to document specific CKD stages (1-5 or ESRD) and underlying causes. The policy clarifies ICD-10-CM code mapping for each CKD stage and establishes documentation requirements for combination coding with diabetes and hypertension.
Florida Blue · Identified Jun 16, 2026Medium impact
Florida Blue Medicare Risk Adjustment Best Practices and Coding Educational Guide, 2023
For Medicare Advantage risk adjustment under the CMS-HCC models V24 and V28, diagnoses must be supported by clear, specific medical record documentation. Chronic conditions must be reported once a year to maintain the patient's HCC risk score, and key status conditions such as amputation or transplant status must also be reported each year. Documentation rules are set out for chronic conditions including chronic kidney disease, diabetes, heart failure, COPD, cancer, major depression and substance use disorders.
Aetna · Identified Oct 17, 2026Low impact
Electrical Stimulation for Nausea, Vomiting, Motion Sickness and Other Selected Indications (CPB 0676, reviewed 2026-10-07)
Aetna clinical policy bulletin 0676 (reviewed October 7, 2026) covers prescription ReliefBand and PrimaBella devices for post-operative or chemotherapy-induced nausea that does not respond to antiemetics and conservative care, and for hyperemesis gravidarum that does not respond to conservative therapy. It treats other transcutaneous acupoint stimulation uses, such as motion sickness, autism, dysmenorrhea and fertility, as experimental, and does not cover over-the-counter disposable ReliefBand devices. The source gives a review date but no effective date.

Watch Z94.0

Get one email when a payer policy names Z94.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z94.0?

There are 18 tracked policy changes affecting code Z94.0, including updates from Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z94.0?

Payers that have issued tracked updates for code Z94.0 include: Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, Aetna, Florida Blue.

How do I get notified when code Z94.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z94.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z94.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Laboratory Testing for Transplantation Rejection 2.02.55

Immunoglobulin Therapy

Donor Lymphocyte Infusion (CPB 0638, reviewed 2026-09-29)

Adoptive Immunotherapy and Cellular Therapy (CPB 0641, reviewed 2026-09-25)

Kidney Transplantation (CPB 0493, reviewed 2026-07-30)

Hepatitis Screening (CPB 0835, reviewed 2025-12-09)

ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) (CPB 0780, reviewed 2026-04-27)

Flow Cytometry, Ektacytometry, DNA Ploidy, and S-phase Fraction (CPB 0351, reviewed 2026-05-21)

Talimogene Laherparepvec (Imlygic) (CPB 0900, reviewed 2026-04-14)

Remote Ischemic Conditioning (CPB 0814, reviewed 2025-11-20)

Near-Infrared Vascular Imaging and Near-Infrared Fluorescence Imaging (CPB 0846, reviewed 2025-12-04)

Donor Lymphocyte Infusion (CPB 0638, reviewed 2025-11-12)

Belimumab (Benlysta) (CPB 0818, reviewed 2026-06-10)

Adoptive Immunotherapy and Cellular Therapy (CPB 0641, reviewed 2025-10-01)

Plasma Exchange

Coding Newsletter - Chronic Kidney Disease

Florida Blue Medicare Risk Adjustment Best Practices and Coding Educational Guide, 2023

Electrical Stimulation for Nausea, Vomiting, Motion Sickness and Other Selected Indications (CPB 0676, reviewed 2026-10-07)

What insurance policy changes affect code Z94.0?

Which payers have updated policy for code Z94.0?

How do I get notified when code Z94.0 policy changes?

Why do payers change policies for code Z94.0?